Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market
(WorldNews Canada)

CHARLESTON, S.C., Feb. 19, 2020 (GLOBE NEWSWIRE) --Aeterna Zentaris Inc.(NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 3,478,261 common shares at a purchase price of $1.29375 per common share in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million. Aeterna...